Pfizer commits $330 million upfront to license three autoimmune CAR-T programs from Starna Therapeutics before human trials — the lead in this delayed November 18 edition. Sanofi’s Infilbray (venglustat) is the first FDA-approved treatment for neurological symptoms of type 3 Gaucher disease, with clearer trial evidence for cognition than for movement alone. Regeneron reports FDA approval of Livsayis (cemdisiran), dosed every 12 weeks for AChR-positive adults with generalized myasthenia gravis. The roundup covers Biogen’s diranersen follow-up in early Alzheimer’s disease, Merck’s halt to Phase 3 nemtabrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma, and the FDA’s plan to expand review sharing for overseas filings.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →